Skip to content
PaperFren

aging

Does mild kidney impairment ruin AD blood tests?

Arslan B, Brum WS, Pola I, et al. · Alzheimer's research & therapy · 2025

Open access · cc by · source: Europe PMC

In 242 TRIAD participants, eGFR related to some plasma AD biomarkers, but adding eGFR did not improve Aβ-positivity prediction beyond age/sex and the biomarker itself.

How this study connects

Role on claims

Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.

Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.

Inspect source passages

Does mild kidney impairment ruin AD blood tests?

These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.

242 TRIAD participants included.

Methods We included 242 participants from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort, comprising cognitively unimpaired individuals (CU; n = 124), mild cognitive impairment (MCI; n = 58), AD dementia ( n = 34), and non-AD dementia ( n = 26) patients all characterized by

Adding eGFR did not improve AIC or AUC for Aβ-positivity models.

we observed no improvements in model fit (Akaike Information Criterion, AIC) or in discriminative performance (AUC) by adding eGFR to a base model including each plasma biomarker, age, and sex.
Read passages in the original paper

Key findings

Levels were highest in CKD stage 3 for some markers (significant for NfL, Aβ42, Aβ40). Many eGFR associations shrank after age/sex/Aβ-PET adjustment; adding eGFR did not improve AIC or AUC for Aβ-positivity. Authors conclude normal-to-mild renal impairment is not clinically decisive for accurate markers like p-tau217.

Methodology

Measured eGFR from plasma creatinine and multiple Simoa plasma biomarkers (Aβ42/40, GFAP, NfL, p-tau isoforms, NTA-tau) in 242 TRIAD participants, then tested associations and Aβ-positivity models with/without eGFR.

Limitations

Few participants had advanced CKD, so results do not rule out clinically important confounding in severe kidney disease.

Related papers in this topic

Same topic cluster — not a recommendation engine.